Thus, these algorithms favor the use of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors because of their efficacy and safety, include thiazolidinediones (TZDs) as "well-validated" agents, and move sulfonylureas (SFUs) to lower priority because of their risk of hypoglycemia, weight gain, and short period of efficacy [24]. The gene discussed is DPP4; the disease is Hypoglycemia.